The association of menstruation of breast cancer patients with chemotherapy regimen and aging period / 肿瘤

ABSTRACT

Objective: We aimed to study the influence of chemotherapeutic regimens and aging of breast cancer patients on chemotherapy-induced amenorrhea (CIA) and to guide the further selection of drugs for endocrine therapy. Methods: We retrospectively studied the chemotherapy-induced amenorrhea (CIA) of the premenopausal breast cancer patients and compare the difference in CIA between the patients who received different chemotherapies or at different aging periods. Results: One hundred and three women were followed up. The difference in the rate of CIA was not statistically significant between the women who received anthracycline-based chemotherapy and docetaxel-based chemotherapy (70.6% vs 61.1%, P = 0.719). The occurrence rate of CIA was significantly higher in older women (> 45 years) than young women ( ≤45 years, P = 0.001). CIA occurred more lately in young women than old women (P = 0.001). Conclusion: Age is an important factor for the CIA. Chemotherapy has less influence on the menstruation of younger women (≤45 years) and most amenorrhea is reversible. For these patients aromatase inhibitors are not recommended for adjuvant endocrine therapy. The effect of docetaxel on menstruation is not greater than anthracycline.